➡️SUBSCRIBE to my channel: [ Ссылка ]

Products mentioned in this video (affiliate links):
iRestore Professional Laser Hair Growth System: [ Ссылка ]

The iRestore helmet is all abuzz on social media, but does it actually work? Is there actually science backing the product for promoting hair loss? The iRestore Professional (and all the iRestore) products rely on a concept called photobiomodulation, a process to describe the absorption of red/near-infrared light energy that has been shown to enhance mitochondrial ATP production and ultimately reduce oxidative stress.

Research suggests that low-level red light therapy may promote growth of human hair while significantly delaying the transition of the hair cycle from the anagen growth phase to the catagen phase. Other research suggests that red light therapy may feature similar effectiveness as topical minoxidil in terms of hair growth, with combination of the two being even more effective. Compared with other interventions for hair loss, there seems to be very few adverse risks when these noninvasive red light products are used appropriately.

SUBSCRIBE:
[ Ссылка ]

#irestore #hairgrowth
_____________
FOLLOW ME!
Instagram: @brandonmilesmay ([ Ссылка ])
Snapchat: @brandonmilesmay
Tik Tok: @brandonmay1915
_____________
Disclaimer: This video is not intended to replace medical advice from a certified healthcare provider.
_____________
References:

Avci P, Gupta GK, Clark J, Wikonkal N, Hamblin MR. Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers Surg Med. 2014;46(2):144-151.

Pillai JK, Mysore V. Role of Low-Level Light Therapy (LLLT) in Androgenetic Alopecia. J Cutan Aesthet Surg. 2021;14(4):385-391.

Yang K, Tang Y, Ma Y, et al. Hair Growth Promoting Effects of 650 nm Red Light Stimulation on Human Hair Follicles and Study of Its Mechanisms via RNA Sequencing Transcriptome Analysis. Ann Dermatol. 2021;33(6):553-561.

Yoon JS, Ku WY, Lee JH, Ahn HC. Low-level light therapy using a helmet-type device for the treatment of androgenetic alopecia: A 16-week, multicenter, randomized, double-blind, sham device-controlled trial. Medicine (Baltimore). 2020;99(29):e21181. doi:10.1097/MD.0000000000021181

свернуть